Key Highlights

  • OrthoPediatrics (NASDAQ:KIDS) is scheduled to report third-quarter results after the close on Tuesday, October 27, 2026, with consensus estimates pointing to a loss of USD 0.21 per share.
  • Second-quarter revenue rose 15% to USD 70.5 million, adjusted EBITDA reached USD 6.8 million and the loss was USD 0.30 per share, unchanged from a year earlier.
  • Full-year revenue guidance was raised to USD 265.0 million to USD 269.0 million, implying 12% to 14% growth, with adjusted EBITDA of about USD 25.0 million reiterated.
  • Scoliosis revenue fell 9% to USD 16.9 million, so a recovery in that segment is the main test of the chief executive's inflection point claim.

The Setup Against Raised Guidance

OrthoPediatrics (NASDAQ:KIDS) is a medical device company focused on children's orthopedic conditions, and it is scheduled to report after the close on Tuesday, October 27, 2026. Consensus estimates call for a loss of USD 0.21 per share. In its release of the second quarter, the company reported revenue of USD 70.5 million, up from USD 61.1 million, a gross margin of 74% and a loss of USD 0.30 per share. It then raised 2026 revenue guidance from USD 263.0 million to USD 267.0 million to a new range of USD 265.0 million to USD 269.0 million. Adjusted EBITDA of about USD 25.0 million and breakeven free cash flow were reiterated. Results cannot be known in advance.

How Segments and Margins Drive the Quarter

OrthoPediatrics (NASDAQ:KIDS) sells implants and instruments to children's hospitals, and its growth comes from trauma and deformity products, which rose 26% to USD 52.6 million in the second quarter. Scoliosis was weaker, down 9% to USD 16.9 million because of the timing of capital placements and fewer international set sales, and management expects it to recover. The consensus loss of USD 0.21 is narrower than the USD 0.30 reported, so it assumes operating leverage, with operating expenses up only 3% against gross profit up 19%. Cash, short-term investments and restricted cash fell to USD 47.9 million, so free cash flow matters. International revenue grew 22% to USD 15.7 million.

Risks and What to Watch

The bull case is revenue growth near 15%, a loss narrower than USD 0.21 and a scoliosis rebound, which would support the view of an inflection and could lift the shares, especially if guidance is raised again. The bear case is a second quarter of scoliosis decline, a loss at or wider than last quarter or cash falling further, which would raise financing concerns and could weigh on the shares. Investors should watch the trauma and deformity growth rate, gross margin near 74%, adjusted EBITDA toward the USD 25.0 million target and the cash balance. The Federal Reserve decision on Wednesday, October 28, 2026 follows.

Where Things Stand

The answer is that OrthoPediatrics (NASDAQ:KIDS) is expected to narrow its loss to USD 0.21 per share, and a scoliosis recovery plus another guidance lift would be the strongest positive signals. Cash of USD 47.9 million makes free cash flow delivery important. The next catalysts are the release after the close on Tuesday, October 27, 2026 and the Federal Reserve decision on Wednesday, October 28, 2026. Consensus figures and guidance are estimates, not guarantees, and this is not investment advice.